An Unusual Presentation of Zollinger-Ellison Syndrome

Emanuele Sinagra\textsuperscript{b} Giovanni Perricone\textsuperscript{b} Cristina Linea\textsuperscript{a}
Luigi Montalbano\textsuperscript{a} Stefania Plano\textsuperscript{b} Rosa Giovanna Simonetti\textsuperscript{b}
Ambrogio Orlando\textsuperscript{b} Claudia Romano\textsuperscript{b} Georgios Amvrosiadis\textsuperscript{b}
Marco Messina\textsuperscript{d} Andrea Scalis\textsuperscript{b} Maria Rosa Rizzuto\textsuperscript{c}
Aroldo Gabriele Rizzo\textsuperscript{c} Mario Cottone\textsuperscript{b}

\textsuperscript{a}Operative Unit of Gastroenterology, \textsuperscript{b}Operative Unit of Internal Medicine and
\textsuperscript{c}Pathology Unit, Palermo University, V. Cervello Hospital, and \textsuperscript{d}Operative Unit
of Oncology, Casa di Cure Orestano, Palermo, Italy

Key Words
Zollinger-Ellison syndrome · Esophageal strictures · Octreoscan · Positron emission
tomography

Abstract
Zollinger-Ellison syndrome is an often progressive, persistent and frequently life-threatening
disease, described for the first time as characterized by ulceration of the upper jejunum,
hypersecretion of gastric acid and non-beta islet cell tumors of the pancreas; this syndrome
is due to the hypersecretion of gastrin. We report a case of Zollinger-Ellison syndrome
presenting as severe esophagitis evolving in stenosis, which demonstrates how a delayed
diagnosis may induce risk of disease spreading. In this setting new diagnostic approaches,
such as somatostatin receptor scanning and positron emission tomography with
68 Ga-labeled octreotide, could be particularly useful, as well as further new therapeutic
options, such as molecular targeted treatments and peptide receptor radionuclide therapy,
though surgery is currently the only form of curative treatment, and the role of the
therapeutic options mentioned needs to be clarified by forthcoming studies.

Introduction

Zollinger-Ellison syndrome (ZES) is an often progressive, persistent and frequently
life-threatening disease, described for the first time as characterized by ulceration of
the upper jejunum, hypersecretion of gastric acid and non-beta islet cell tumors of the
pancreas; this syndrome is due to the hypersecretion of gastrin \cite{1} secondary to a
gastrinoma. This is a neuroendocrine tumor derived from multipotent stem cells of
endodermal origin. It can be sporadic (in 80% of cases) or associated with multiple endocrine neoplasia type 1 (MEN1). 70% of gastrinomas arise from the duodenum, the remainder from the pancreas or less often from lymph nodes adjacent to the pancreas.

MEN1 is an autosomal dominant inherited syndrome caused by mutations of the MEN1 tumor suppressor gene on chromosome 11q13 [2]. MEN1 gene mutations are also identified in 33% of sporadic gastrinomas [3]. MEN1 is characterized by the combined occurrence of primary hyperparathyroidism (>90%), pancreaticoduodenal endocrine neoplasms (65–75%) and tumors of the anterior pituitary gland (30–65%). Pancreaticoduodenal endocrine tumors (PETs) are of outstanding interest because malignant PETs represent the most common cause of death within MEN1 syndrome [4, 5]. This is especially true for gastrinomas, despite effective control of acid hypersecretion and its complications by proton pump inhibitors (PPIs) [6, 7].

The incidence of ZES in the United States initially ranged from 0.1 to 1% of patients with peptic ulcer disease [8], but this percentage may be underestimated because patients with ZES often presented with symptoms similar to those of Helicobacter pylori-related disease or to those caused by typical peptic ulcer disease related to nonsteroidal anti-inflammatory drugs. In fact these symptoms may be controlled by a standard dose of PPIs, thus such patients are not tested for hypergastrinemia [8].

ZES is usually diagnosed in the fifth decade of life, and although it may occur in children and adolescents or the elderly, it is diagnosed between the age of 20 and 60 in 90%. The male-to-female ratio ranges between 1.5:1 and 2:1. Over 90% of patient with ZES develop peptic ulcers, often solitary ulcers < 1 cm in diameter (75% of ulcers in the first portion of the duodenum, 14% in the distal duodenum and 11% in the jejunum). These ulcers recur much more often than in patients with sporadic ulcer disease. Other prominent clinical features are abdominal pain (75%) and diarrhea (73%), which are the most frequent symptoms, while heartburn and weight loss are reported by 44 and 17% of patients. Gastrointestinal bleeding is the initial presentation in 25% of patients, while nephrocalcinosis and renal colic are more frequent in MEN1 compared with sporadic tumors. Metastatic disease is evident at the time of diagnosis in one third of patients with gastrinoma; the liver is the most common site of metastasis [8].

For the diagnosis of ZES there are three tests: fasting serum gastrin concentration, secretin stimulation test and gastric acid secretion studies. Of these, only the first and the second are used routinely. After the diagnosis of ZES is made, the gastrinoma must be located and staged [8]. We report a case of ZES presenting as severe esophagitis evolving in stenosis, which demonstrates how a delayed diagnosis may induce risk of disease spreading.

Case Report

A 61-year-old woman was admitted to our hospital with a 3-year history of nausea and vomiting not related to food and sometimes associated with watery diarrhea. During the last year she had lost about 20% of her body weight (her previous weight was 78 kg, and at admission to our unit her weight was 64 kg). Because of worsening of these symptoms she was admitted to our unit.

In the previous years the patient had been admitted to other hospitals. Esophagogastro-duodenoscopy had been performed 3 years before, showing a large H. pylori-positive bulbar ulcer (treated with eradicant triple therapy) and esophagitis. Abdominal ultrasonography and computed
tomography were performed to exclude intestinal disease. These showed some focal hepatic lesions which were interpreted as angiomylipomatosis. The patient was discharged from the hospital and treated with PPIs and prokinetics, without any clinical benefit.

On admission to our unit, esophagogastroduodenoscopy showed severe esophagitis with large mucosal ulcerations and an esophageal stenosis (fig. 1). For this reason gastrin and chromogranin levels were determined, resulting in values over the upper normal limits (>1,490 μl/ml and >540 μl/ml, respectively). ZES was then suspected, so abdominal ultrasonography was performed, showing many hepatic focal lesions with a contrastographic pattern of repetitive lesions.

Octreoscan revealed only many enhancing lesions (somatostatin receptor subtype 2 and 5 positive) in the liver. The serrated esophageal stenosis did not allow us to perform endoscopic ultrasonography to try to find any primary lesions of the pancreas. Abdominal magnetic resonance imaging did not detect pancreatic or intestinal lesions, thus a biopsy of the liver lesion was performed and the histology diagnosed a gastrinoma. The immunohistochemical profile showed 80% cell positivity for gastrin (as shown in fig. 2, with a scale bar of 100 μm) and chromogranin (as shown in fig. 3, with a scale bar of 100 μm). In addition, no mutation of the MEN1 gene was found, so MEN1 was excluded.

For this reason total parenteral nutrition and PPI i.v. were started, obtaining a reduction in the frequency of vomiting and diarrhea. An endoscopic pneumatic dilation of the esophageal stenosis was performed, with an improvement of both dysphagia and esophageal canalization. A further endoscopic ultrasonography was performed to detect primary lesions of the pancreas, but the result was negative. The patient was discharged with a high-dose PPI therapy, with the program to perform periodical esophageal endoscopic dilation and to start chemotherapy with octreotide and receptorial radiotherapy with 1,850 MBq of 90Y-Dotatoc.

Discussion

This case reported shows that severe necrotic esophagitis unresponsive to a standard dosage of PPI may be due to ZES [9]. In the literature few cases of necrotic esophagitis have been described [10–12]. The consequence of a delayed diagnosis may be severe esophageal stricture and metastatic disease [13, 14], like in our patient. High doses of PPI together with endoscopic pneumatic dilation led to resolution of esophageal symptoms.

Little is known about the risk of severe esophagitis in ZES. A prospective study has evaluated esophageal involvement and its complications in ZES [8]. The authors show that this complication is more severe in ZES associated with MEN1 than in sporadic ZES and they also identify important factors for the pathogenesis that need to be incorporated into the long-term treatment. In Jensen’s series [8], 10 patients out of 215 (0.4%) with sporadic ZES developed esophageal strictures. Our case was a sporadic ZES which developed strictures. It is possible that the delayed diagnosis was the cause of this complication. A high dosage of PPIs together with endoscopic pneumatic dilation kept the patients asymptomatic.

Though the two major modalities for tumor identification are somatostatin receptor scanning (SRS) and single photon emission computed tomography, particularly useful in identifying liver and bone metastases [15], sometimes the identification of gastrinoma is difficult. When a strong clinical suspicion persists despite negative results, other techniques have been used in the past, including dual phase helical computed tomography, magnetic resonance imaging, angiography, arterial stimulation and venous sampling, and fluorodeoxyglucose-positron emission tomography (FDG-PET) [16]. To date, with the improvement of the knowledge
about the pathophysiology of the disease, further techniques could be used for the detection of both primary tumors and metastases. Multi-detector computed tomography could be performed not only to demonstrate small primary tumors and liver metastases, but also tumor-associated desmoplastic fibrosis around the primary tumor and lymph node metastases. Other new approaches performed to visualize neuroendocrine tumors are $^{11}$C- and $^{18}$F-labeled L-Dopa PET, which show a higher sensitivity (65%) than FDG-PET (29%) and SRS (57%), but a lower sensitivity than morphologic imaging by computed tomography and magnetic resonance imaging (73%) and by $^{11}$C-5-hydroxytryptophan-PET. PET with 68 Ga-labeled octreotide (such as $^{68}$Ga-DOTA-TOC, $^{68}$Ga-DOTA-NOC and $^{68}$Ga-DOTA-TATE) has also been evaluated in a few published reports, also showing a higher sensitivity than SRS. In selected cases tumor localization can only be achieved through laparotomy by direct palpation, duodenal transillumination or intraoperative ultrasound. The precise role of these new approaches in the treatment algorithm of neuroendocrine tumors will hopefully be clarified by forthcoming studies [17].

**Disclosure Statement**

The authors declare no conflicts of interest.

---

**Fig. 1.** Severe esophagitis with a tight lower esophageal stenosis.
Fig. 2. Liver immunohistochemistry with cell positivity for gastrin (arrows), scale bar = 100 μm.

Fig. 3. Liver immunohistochemistry with cell positivity for chromogranin (arrows), scale bar = 100 μm.
References

1. Zollinger RM, Ellison EH: Primary peptic ulcerations of the jejunum associated with islet cells tumors of the pancreas. Ann Surg 1955;142:709–723.
2. Isenberg JI, Walsh JH, Grossman MI: Zollinger-Ellison syndrome. Gastroenterology 1973;65:140–165.
3. Chandrasekharappa SC, Guru SC, Manickam P, et al: Positional cloning of the gene for multiple endocrine neoplasia-type 1 (MEN1). Science 1997;276:404–407.
4. Zhuang Z, Vortmeyer AO, Pack S, et al: Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997;57:4682–4686.
5. Wilkinson S, Teh BT, Davey KR, McArdle JP, Young M, Shepherd J: Cause of death in multiple endocrine neoplasia type 1. Arch Surg 1993;128:683–690.
6. Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA, Norton JA: Lethality of multiple endocrine neoplasia type I. World J Surg 1998;22:581–587.
7. Fendrich V, Langer P, Waldfmann J, Bartsch DK, Rothmund M: Management of sporadic and multiple endocrine neoplasia type 1 gastrinoma. Br J Surg 2007;94:1131–1141.
8. Hoffmann KM, Gibril F, Enutsuh LK, et al: Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett’s esophagus. J Clin Endocrinol Metab 2006;91:204–212.
9. Agha FP: Esophageal involvement in Zollinger-Ellison syndrome. AJR Am J Roentgenol 1985;144:721–725.
10. Ng T, Maziak DE, Shamji FM: Esophageal perforation: a rare complication of Zollinger-Ellison syndrome. Ann Thorac Surg 2001;72:592–593.
11. Bondeson AG, Bondeson L, Thompson NW: Stricture and perforation of the esophagus: overlooked threats in the Zollinger-Ellison syndrome. World J Surg 1990;14:361–363; discussion 363–364.
12. Hirschowitz BI: Gastric secretion of acid and pepsin in patients with esophageal stricture and appropriate controls. Dig Dis Sci 1996;41:2115–2122.
13. Gibril F, Schumann M, Pace A, Jensen RT: Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004;83:43–83.
14. Jensen RT, Gardner JD: Gastrinoma; in Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA (eds): The Pancreas: Biology, Pathobiology, and Disease, ed 2. New York, Raven Press, 1993, p 947.
15. Gibril F, Doppman JL, Reynolds JC, et al: Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J Clin Oncol 1998;16:1040–1053.
16. Thom AK, Norton JA, Doppman JL, et al: Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery 1992;112:1002–1008; discussion 1008–1009.
17. Oeberg K: Gastrointestinal carcinoid tumors (gastrointestinal neuroendocrine tumors) and the carcinoid syndrome; in Feldman M, Friedman LS, Brandt LJ (eds): Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, vol 2, ed 9. Philadelphia, Saunders Elsevier, 2010, pp 485–489.